C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding C4 Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 114 | 1 | 117 | +4 |
| Shares | 39.4M | 12.7K | 39.2M | −213.8K (−0.5%) |
| Value | $345.9M | $111.0K | $231.4M | −$114.4M (−33.1%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held C4 Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jump Financial, LLC | 36,000 | $212.4K | 0.01% |
| Susquehanna Fundamental Investments, LLC | 32,496 | $191.7K | 0.00% |
| UBS Asset Management Americas Inc | 29,293 | $172.8K | 0.00% |
| Alpine Global Management, LLC | 18,574 | $110.0K | 0.04% |
| Connor, Clark & Lunn Investment Management Ltd. | 14,457 | $85.3K | 0.00% |
| Aquatic Capital Management LLC | 13,800 | $80.0K | 0.01% |
| American Century Companies Inc | 11,986 | $70.7K | 0.00% |
| CI Private Wealth, LLC | 11,380 | $67.1K | 0.00% |
| Principal Financial Group Inc | 11,365 | $67.1K | 0.00% |
| Corton Capital Inc. | 10,526 | $62.1K | 0.05% |
| HSBC Holdings PLC | 10,155 | $58.9K | 0.00% |
| Quantbot Technologies LP | 5,093 | $30.0K | 0.00% |
| Point72 Middle East FZE | 1,916 | $11.3K | 0.00% |
| Advisor Group Holdings, Inc. | 185 | $1.00K | 0.00% |
| Steward Partners Investment Advisory, LLC | 100 | $590 | 0.00% |
| Accurate Wealth Management, LLC | 31 | $245 | 0.00% |
| CWM, LLC | 46 | $0 | 0.00% |
Sold out (13)
Institutions that held C4 Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Pictet Asset Management SA | 1,305,349 | $11.4M |
| Perceptive Advisors LLC | 766,231 | $6.72M |
| T. Rowe Price Investment Management, Inc. | 547,667 | $4.80M |
| Voloridge Investment Management, LLC | 107,568 | $943.0K |
| HRT Financial LP | 57,088 | $500.0K |
| Trexquant Investment LP | 31,512 | $276.0K |
| Alps Advisors Inc | 26,696 | $234.0K |
| Tudor Investment Corp Et Al | 24,134 | $212.0K |
| Schonfeld Strategic Advisors LLC | 23,861 | $210.0K |
| Captrust Financial Advisors | 14,822 | $130.0K |
| B. Metzler seel. Sohn & Co. AG | 14,700 | $129.0K |
| Ensign Peak Advisors, Inc | 7,230 | $63.0K |
| Wells Fargo & Company | 6,209 | $54.0K |
Not filed for Q4 2022 yet (1)
Institutions that held C4 Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Regentatlantic Capital LLC | 12,695 | $111.0K |